Summary

The multitargeted agent sorafenib is the first therapy that has shown promise in a Phase 3 trial to extend progression-free survival in patients with metastatic differentiated thyroid cancer that is refractory to standard radioactive iodine (RAI) therapy. This article discusses interim results from a double-blind, placebo-controlled randomized Phase 3 Study of Sorafenib in Locally Advanced or Metastatic Patients With Radioactive Iodine Refractory Thyroid Cancer [DECISION; NCT00984282; Brose MS et al. J Clin Oncol 2013 (suppl; abstr 4)], for the treatment of patients with RAI refractory differentiated thyroid cancer.